Clinical and Experimental Medicine

, Volume 10, Issue 3, pp 179–184 | Cite as

Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women

  • Ramazan Sari
  • Esin Eray
  • Sabahat Ozdem
  • Halide Akbas
  • Erkan Coban
Original Article


Sibutramine and metformin are drugs commonly used to obtain weight loss. We aimed to compare the effects of sibutramine alone with that of sibutramine plus metformin combination on weight loss, insulin sensitivity, leptin and C reactive protein in obese women. Seventy obese women were included. After a diet period of month (baseline), each individual was randomly assigned to receive 15 mg sibutramine (sibutramine group; n = 36) or 15 mg sibutramine plus 1,700 mg metformin per day (sibutramine plus metformin group; n = 34) during the next 12 months. Body weight, insulin resistance by the homeostasis model assessment model (HOMA-IR), leptin and C reactive protein were measured at baseline, after 3 months and after 12 months. Mean weight losses in sibutramine and sibutramine plus metformin groups were 5.3 ± 4.0% (P < 0.001) and 6.8 ± 3.9% (P < 0.001) after 3 months, and 10.5 ± 4.4% (P < 0.001) and 15.7 ± 4.6% (P = 0.007) after 12 months, respectively. HOMA-IR value also decreased in both sibutramine (P = 0.045 and P = 0.002) and sibutramine plus metformin groups (P = 0.04 and P = 0.015) after 3 and 12 months, respectively. Similarly, serum leptin levels decreased in both sibutramine (P = 0.04, P = 0.01) and sibutramine plus metformin groups (P = 0.023, P = 0.025) after 3 and 12 months, respectively. There was also significant reductions in serum C reactive protein levels in both sibutramine (P = 0.045, P = 0.02) and sibutramine plus metformin groups (P = 0.007, P = 0.001) after 3 and 12 months, respectively. These decrements of body weight, HOMA-IR, serum leptin and C reactive protein levels were not statistical significance between these two groups both after 3 and 12 months (P > 0.05). Combination of sibutramine with metformin did not result in any further effects on weight loss, insulin resistance, leptin and C reactive protein levels when compared to sibutramine alone.


Obesity Insulin resistance Leptin Inflammation Metformin Sibutramine 


Conflict of interest statement

We declare that we have no conflict of interest related to the publication of this manuscript.


  1. 1.
    Larsson B, Björntorp P, Tibblin G (1981) The health consequences of moderate obesity. Int J Obes Relat Metab Disord 5:97–106Google Scholar
  2. 2.
    Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE (1995) Body weight and mortality among women. N Engl J Med 333:677–685CrossRefPubMedGoogle Scholar
  3. 3.
    Heilbronn LK, Clifton PM (2002) C-reactive protein and coronary artery disease: influence of obesity, caloric restriction and weight loss. J Nutr Biochem 13(6):316–321CrossRefPubMedGoogle Scholar
  4. 4.
    Dvorakova-Lorenzova A, Suchanek P, Havel PJ, Stavek P, Karasova L, Valenta Z, Tintera J, Poledne R (2006) The decrease in C-reactive protein concentration after diet and physical activity induced weight reduction is associated with changes in plasma lipids, but not interleukin-6 or adiponectin. Metabolism 55(3):359–365CrossRefPubMedGoogle Scholar
  5. 5.
    Sharman MJ, Volek JS (2004) Weight loss leads to reductions in inflammatory biomarkers after a very-low-carbohydrate diet and a low-fat diet in overweight men. Clin Sci (Lond) 107(4):365–369CrossRefGoogle Scholar
  6. 6.
    Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17(1):4–12PubMedGoogle Scholar
  7. 7.
    Coban E, Sari R (2004) The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients. Endocr Res 30(3):343–349CrossRefPubMedGoogle Scholar
  8. 8.
    Pi-Sunyer FX (1996) A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther 18:1006–1036CrossRefPubMedGoogle Scholar
  9. 9.
    Goldstein DJ (1992) Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 16:397–415PubMedGoogle Scholar
  10. 10.
    Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C (1995) Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40–64 years. Am J Epidemiol 141:1128–1141PubMedGoogle Scholar
  11. 11.
    Lean MEJ (1997) Sibutramine: a review of clinical efficacy. Int J Obes Relat Metab Disord 21:30S–36SGoogle Scholar
  12. 12.
    Luque CA, Rey JA (1999) Sibutramine: a serotonin re-uptake inhibitor for the treatment of obesity. Ann Pharmacother 33:968–978CrossRefPubMedGoogle Scholar
  13. 13.
    Arterburn DE, Crane PK, Veenstra DL (2004) The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 164(9):994–1003CrossRefPubMedGoogle Scholar
  14. 14.
    Gokcel A, Gumurdulu Y, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N (2002) Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 4:49–55CrossRefPubMedGoogle Scholar
  15. 15.
    Baranowska B, Wolinska-Witort E, Martynska L, Chmielowska M, Mazurczak-Pluta T, Boguradzka A, Baranowska-Bik A (2005) Sibutramine therapy in obese women—effects on plasma neuropeptide Y (NPY), insulin, leptin and beta-endorphin concentrations. Neuro Endocrinol Lett 26(6):675–679PubMedGoogle Scholar
  16. 16.
    Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS (2005) A review of the metabolic effects of sibutramine. Curr Med Res Opin 21(3):457–468CrossRefPubMedGoogle Scholar
  17. 17.
    Wu J, Lei MX, Chen HL (2003) Serum leptin and insulin resistance in obesity and effects of sibutramine on them. Hunan Yi Ke Da Xue Xue Bao 28(6):605–607PubMedGoogle Scholar
  18. 18.
    Valsamakis G, McTernan PG, Chetty R, Al Daghri N, Field A, Hanif W, Barnett AH, Kumar S (2004) Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 53(4):430–434CrossRefPubMedGoogle Scholar
  19. 19.
    Yip I, Go VL, Hershman JM, Wang HJ, Elashoff R, DeShields S, Liu Y, Heber D (2001) Insulin-leptin-visceral fat relation during weight loss. Pancreas 23(2):197–203CrossRefPubMedGoogle Scholar
  20. 20.
    Diamanti-Kandarakis E, Kouli C, Tsianeteli T, Bergiele A (1998) Therpeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 138:269–274CrossRefPubMedGoogle Scholar
  21. 21.
    Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure while facilitating normal menses and pregnancy. Metabolism 43:647–654CrossRefPubMedGoogle Scholar
  22. 22.
    Kim YW, Kim JY, Park YH, Park SY, Won KC, Choi KH, Huh JY, Moon KH (2006) Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes 55(3):716–724CrossRefPubMedGoogle Scholar
  23. 23.
    Carter AM, Bennett CE, Bostock JA, Grant PJ (2005) Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus. Diabet Med 22(9):1282–1284CrossRefPubMedGoogle Scholar
  24. 24.
    Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, Marcovina S, Mather K, Orchard T, Ratner R, Barrett-Connor E (2005) Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 54(5):1566–1572CrossRefPubMedGoogle Scholar
  25. 25.
    Foster GD, Wadden TA, Vogt RA (1997) What is reasonable weight loss?: patients’ expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 65:79–85CrossRefPubMedGoogle Scholar
  26. 26.
    Weintraub M, Sundaresan PR, Madan M, Schuster B, Balder A, Lasagna L, Cox C (1992) Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 51:586–594PubMedGoogle Scholar
  27. 27.
    National Heart, Lung, and Blood Institute (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report (review). Obes Res 6(suppl 2):51S–209SGoogle Scholar
  28. 28.
    World Health Organization (1998) Prevention and management of the global epidemic of obesity: report of the WHO consultation on obesity. World Health Organization, Geneva Report WHO/NUT/NCD/98.1.Google Scholar
  29. 29.
    Arslanian SA, Lewy V, Danadian K, Saad R (2002) Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: Amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 87(4):1555–1559CrossRefPubMedGoogle Scholar
  30. 30.
    Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels, in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 85:2767–2774CrossRefPubMedGoogle Scholar
  31. 31.
    Kay JP, Alemzadeh R, Langley G, D’Angelo L, Smith P, Holshouser S (2001) Benefical effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 50(12):1457–1461CrossRefPubMedGoogle Scholar
  32. 32.
    Freemark M, Bursey D (2001) The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 107(4):E55CrossRefPubMedGoogle Scholar
  33. 33.
    Wood PD, Stefanick M, Dreon DM, Wood PD, Stefanick ML, Dreon DM, Frey-Hewitt B, Garay SC, Williams PT, Superko HR, Fortmann SP, Albers JJ, Vranizan KM (1988) Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med 319:1173–1179CrossRefPubMedGoogle Scholar
  34. 34.
    Smith FJ, Rivera I, Tanenbaum R, Smith W, Campfield LA (1998) Weight loss reverses decreased sensitivity to exogenous ob protein (leptin) in diet-induced obese mice. Int J Obes 22(Supplement 3):41–46Google Scholar
  35. 35.
    Atkinson RL, Blank RC, Schumacher D, Dhurandhar NV, Ritch DL (1997) Long-term drug treatment of obesity in a private practice setting. Obes Res 5:578–586PubMedGoogle Scholar
  36. 36.
    Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM (2000) Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 8(6):431–437CrossRefPubMedGoogle Scholar
  37. 37.
    Sari R, Balci MK, Cakir M, Altunbas H, Karayalcin U (2004) Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res 30(2):159–167CrossRefPubMedGoogle Scholar
  38. 38.
    Sari R, Balci MK, Coban E, Yazicioglu G (2004) Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. Int J Obes Relat Metab Disord 28(8):1059–1063CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Ramazan Sari
    • 1
  • Esin Eray
    • 1
  • Sabahat Ozdem
    • 2
  • Halide Akbas
    • 2
  • Erkan Coban
    • 3
  1. 1.Department of Internal Medicine, Division of Endocrinology and Metabolism, School of MedicineAkdeniz UniversityAntalyaTurkey
  2. 2.Department of Clinical Chemistry, Central Laboratory, School of MedicineAkdeniz UniversityAntalyaTurkey
  3. 3.Department of Internal Medicine, School of MedicineAkdeniz UniversityAntalyaTurkey

Personalised recommendations